clinical trials

September 19, 2017September 19, 2017

Tezepelumab Reduces Exacerbation Rates in Patients with Severe Asthma, Trial Results Show

Asthma, News

Patients with severe and uncontrolled asthma who took tezepelumab had significantly lower annual asthma exacerbation rates than those on placebo, according to the latest results of the PATHWAY Phase 2b trial. ... Read more

September 14, 2017September 14, 2017

Synairgen and Pharmaxis’ Fibrosis Therapy Candidate Is Heading for Phase 1 Clinical Trial

Idiopathic Pulmonary Fibrosis, News

A potential pulmonary fibrosis therapy that Synairgen and Pharmaxis have been working on is heading for a Phase 1 clinical trial. The two created PXS-5382A as a treatment for idiopathic pulmonary fibrosis (IPF) and other ... Read more

September 13, 2017September 13, 2017

INJOURNEY Trial Data Shows Ofev-Esbriet Combo Is Safe and IPF Patients Tolerate It Well

Idiopathic Pulmonary Fibrosis, News

A combination of Boehringer Ingelheim‘s Ofev (nintedanib) and Genentech’s Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) was safe and well tolerated, according to the latest data from the Phase 4 INJOURNEY trial. ... Read more

August 28, 2017August 28, 2017

PharmAkea Completes Phase 1 Clinical Trial of Pulmonary Fibrosis Therapy PAT-1251

Idiopathic Pulmonary Fibrosis, News

PharmaAkea has completed a Phase 1 clinical trial indicating that its PAT-1251 therapy binds with an enzyme associated with pulmonary fibrosis. That suggests that it could be an effective treatment for ... Read more

August 22, 2017August 29, 2017

North Carolina Advances in Stem Cell Therapy for Lung Diseases Could Lead to Clinical Trial Soon

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

University of North Carolina Health Care researchers have made strides toward a stem cell treatment for lung diseases such as pulmonary fibrosis, COPD, and cystic fibrosis. In fact, they are discussing ... Read more

August 14, 2017August 14, 2017

Potential Therapy, GLPG1690, Seen to Halt Worsening of Lung Fibrosis in Phase 2 Trial

Idiopathic Pulmonary Fibrosis, News

Topline results from a Phase 2a clinical trial show that GLPG1690 successfully halted the worsening of idiopathic pulmonary fibrosis (IPF) in patients, its developer, the Belgian biotechnology firm Galapagos, announced. A double-blind, randomized, placebo-controlled trial, ... Read more

August 11, 2017August 11, 2017

Pamrevlumab Can Slow Progression of Pulmonary Fibrosis, Phase 2 Clinical Trial Suggests

News

Pulmonary fibrosis patients taking pamrevlumab had less than half the decline in a measure of lung function over 48 weeks than those receiving a placebo, a Phase 2 clinical trial indicates. The ... Read more

July 24, 2017July 24, 2017

Real-world Safety of Ofev and Esbriet Matches Trial Reports, Despite Office Patients Older, Sicker

Idiopathic Pulmonary Fibrosis, News

Patients treated with Ofev (nintedanib) or Esbriet (pirfenidone) for pulmonary fibrosis in a real-world setting have similar rates of side effects as those reported in clinical trials testing the drugs, despite ... Read more

July 20, 2017July 20, 2017

Samumed Completes Phase 1 Study of Potential IPF Treatment with Positive Results

Idiopathic Pulmonary Fibrosis, News

Samumed has successfully completed a Phase 1 clinical trial in healthy individuals to evaluating a potential therapy — a nebulized inhalation solution called SM04646 — that treats idiopathic pulmonary fibrosis (IPF). The positive ... Read more

July 11, 2017July 11, 2017

Trial Underway in Rare Lung Disease That Can Cause PF and Targets People from Puerto Rico

News

Vanderbilt University researchers are sponsoring the first major study of a rare lung disease that disproportionately affects people from Puerto Rico and can cause pulmonary fibrosis. Called Hermansky-Pudlak syndrome (HPS), the ... Read more